Drug intelligence / Profile preview

ANS07

Development stage: Preclinical
Lead developer: Avistone Biotechnology

Overview

ANS07 is a preclinical-stage drug candidate being developed by Avistone Pharmaceutical for the treatment of solid tumors. As an early-stage asset in the company's pipeline, its specific molecular target and therapeutic modality (such as small molecule or monoclonal antibody) have not yet been publicly disclosed. Avistone Pharmaceutical is a biotechnology company focused on precision oncology, and ANS07 represents part of its effort to expand its portfolio of targeted therapies beyond its lead programs, vebreltinib and andamertinib.

Beyond the preview

Go deeper on ANS07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANS07.

Explore the full profile